Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
Status unconfirmed · Phase 2 · Has a placebo group
Conditions studied: Mast Cell Activation Syndrome
In brief
To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.
Key facts
- Study ID
- NCT05449444
- Run by
- AB Science
- People needed
- 72
- Starts
- 2022-07-01
- Expected to finish
- 2024-12-31
- Last updated by the study team
- 2023-02-06
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- St Charles Clinical Research — Weldon Spring, Missouri, United States (enrolling)
- Centre Hospitalier Universitaire Amiens-Picardie — Amiens, France (enrolling)
- Necker-Enfants Malades Hospital, Centre de référence des Mastocytoses (CEREMAST) — Paris, France (enrolling)
- CHU Toulouse — Toulouse, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.